These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8958378)

  • 21. [Fulminant liver failure induced by flutamide].
    Rodríguez Gómez SJ; Martínez Moreno J; Martín Arribas MI; Pérez Villoria A; De la Serna Higuera C; Betancourt González A
    Rev Esp Enferm Dig; 2000 Jun; 92(6):411. PubMed ID: 10985104
    [No Abstract]   [Full Text] [Related]  

  • 22. Fixed drug eruption caused by cyproterone acetate.
    Galindo PA; Borja J; Feo F; Gómez E; Chamorro R; Encinas C; García R
    Allergy; 1998 Aug; 53(8):813. PubMed ID: 9722234
    [No Abstract]   [Full Text] [Related]  

  • 23. Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia.
    Mallari R; Sinclair RD
    Int J Dermatol; 2002 Dec; 41(12):946-7. PubMed ID: 12492998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hepatotoxicity induced by cyproteron acetate in the prostate carcinoma treatment - a case report].
    Vodička M; Sálek T; Röderová E; Cerný D
    Klin Onkol; 2013; 26(1):47-8. PubMed ID: 23528173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Should cyproterone acetate be removed from our prescriptions?].
    Plu-Bureau G
    Gynecol Obstet Fertil Senol; 2019 Dec; 47(12):823-824. PubMed ID: 31634588
    [No Abstract]   [Full Text] [Related]  

  • 26. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
    Manso G; Thole Z; Salgueiro E; Revuelta P; Hidalgo A
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):253-9. PubMed ID: 16294367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer].
    Satoh T; Egawa S; Katsuta M; Iwamura M; Uchida T; Koshiba K
    Nihon Hinyokika Gakkai Zasshi; 1997 Jul; 88(7):694-6. PubMed ID: 9267134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fulminant liver failure caused by cyproterone.
    Famularo G; Minisola G; Grieco A; Miele L
    Dig Liver Dis; 2005 Sep; 37(9):718-9. PubMed ID: 15936995
    [No Abstract]   [Full Text] [Related]  

  • 29. Severe hepatocellular dysfunction following cyproterone acetate therapy.
    Parys BT; Hamid S; Thomson RG
    Br J Urol; 1991 Mar; 67(3):312-3. PubMed ID: 1827039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE
    Eur Urol; 1990; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract]   [Full Text] [Related]  

  • 31. CD8+ lymphocytic pneumonitis in a patient receiving cyproterone acetate.
    Similowski T; Orcel B; Derenne JP
    South Med J; 1997 Oct; 90(10):1048-9. PubMed ID: 9347820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Fatal subfulminant hepatitis caused by cyproterone acetate].
    Antoni M; Bourlière M; Toullec J; Maillot A; Botta-Fridlund D; Gauthier A
    Gastroenterol Clin Biol; 1991; 15(10):772-3. PubMed ID: 1840042
    [No Abstract]   [Full Text] [Related]  

  • 33. [Fatal hepatitis caused by cyproterone acetate].
    Bressollette L; Dubois A; Carlhant D; Morand C; Mottier D; Riche C
    Therapie; 1994; 49(2):153. PubMed ID: 7817350
    [No Abstract]   [Full Text] [Related]  

  • 34. Cyproterone acetate in paraphilia.
    Panesar N; Allard B; Pai N; Valachova I
    Aust N Z J Psychiatry; 2011 May; 45(5):428. PubMed ID: 21417675
    [No Abstract]   [Full Text] [Related]  

  • 35. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient.
    Cebula H; Pham TQ; Boyer P; Froelich S
    Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919
    [No Abstract]   [Full Text] [Related]  

  • 36. [Cyproterone acetate. Its value in the treatment of prostatic cancer. Apropos of 45 cases].
    Tobelem G; Arvis G
    Therapie; 1988 May; 43(3):179-82. PubMed ID: 2971278
    [No Abstract]   [Full Text] [Related]  

  • 37. Cyproterone acetate and risk of meningioma: a nationwide cohort study.
    Mikkelsen AP; Greiber IK; Scheller NM; Hilden M; Lidegaard Ø
    J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):222-223. PubMed ID: 34187864
    [No Abstract]   [Full Text] [Related]  

  • 38. Diane-35 (cyproterone acetate): safety concerns.
    Wooltorton E
    CMAJ; 2003 Feb; 168(4):455-6. PubMed ID: 12591790
    [No Abstract]   [Full Text] [Related]  

  • 39. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
    Thorpe SC; Azmatullah S; Fellows GJ; Gingell JC; O'Boyle PJ
    Eur Urol; 1996; 29(1):47-54. PubMed ID: 8821690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fulminant hepatic failure associated with bicalutamide.
    Schellhammer PF
    Urology; 1997 Nov; 50(5):827. PubMed ID: 9372905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.